NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-266-2011-0-DE-42 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage DE EP 18175738.6 Issued
NCI E-266-2011-0-CZ-41 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage CZ EP 18175738.6 Issued
NCI E-266-2011-0-ES-43 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage ES EP 18175738.6 Issued
NCI E-266-2011-0-SE-52 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage SE EP 18175738.6 Issued
NCI E-266-2011-0-CH-40 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage CH EP 18175738.6 Issued
NCI E-266-2011-0-TR-55 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage TR EP 18175738.6 Issued
NCI E-266-2011-0-FR-44 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage FR EP 18175738.6 Issued
NCI E-178-2009-0-US-05 ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES US CON 15/997,477 Abandoned
NCATS E-096-2018-0-US-01 PROCESS FOR SYNTHESIS AND PURIFICATION OF (2R,6R)-HYDROXYNORKETAMINE US 62/680,183 Abandoned
NHLBI E-219-2018-1-US-01 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging US 62/680,185 Abandoned
NIBIB E-062-2017-0-IL-05 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging IL National Stage 2042-10-27 Abandoned
NIBIB E-062-2017-0-IE-01 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging IE EP 18810466.5 Abandoned
NIBIB E-062-2017-0-DE-01 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging DE EP 18810466.5 Abandoned
NIBIB E-062-2017-0-FR-01 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging FR EP 18810466.5 Abandoned
NIBIB E-062-2017-0-CH-01 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging CH EP 18810466.5 Abandoned
NIBIB E-062-2017-0-EP-04 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging EP National Stage 18810466.5 Abandoned
NIBIB E-062-2017-0-GB-01 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging GB EP 18810466.5 Abandoned
NIBIB E-062-2017-0-CN-03 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging CN National Stage 201880035990.9 Abandoned
NIDCR E-152-2017-0-DE-06 FORMATION OF STABLE CARTILAGE DE EP 18737743.7 Issued
NIDCR E-152-2017-0-FR-07 FORMATION OF STABLE CARTILAGE FR EP 18737743.7 Issued
NIDCR E-152-2017-0-GB-08 FORMATION OF STABLE CARTILAGE GB EP 18737743.7 Issued
NIDCR E-152-2017-0-EP-03 FORMATION OF STABLE CARTILAGE EP National Stage 18737743.7 Issued
NHGRI E-110-2017-0-PCT-02 Methods of Detecting and Treating GATM-Related Renal Disorders PCT PCT PCT/US2018/035423 Expired
NIDCR E-152-2017-0-PCT-02 FORMATION OF STABLE CARTILAGE PCT PCT PCT/US2018/035448 Expired
NIBIB E-062-2017-0-PCT-02 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging PCT PCT PCT/US2018/035303 Expired
NHLBI E-217-2015-0-US-06 Fluorescent Nanodiamonds As Fiducial Markers For Microscopy And Fluorescence Imaging US National Stage 15/780,388 Abandoned
NCATS E-299-2012-0-US-07 BMP Inhibitors and Methods of Use Thereof US CON 15/994,604 Abandoned
NCI E-015-2018-0-US-01 METHOD FOR TREATING OR PREVENTING PERIODONTITIS WITH GEOPROPOLIS EXTRACT US 62/678,774 Abandoned
NIAID E-103-2014-3-AU-09 Antibody Evolution Immunogens AU DIV 2018203805 Abandoned
NIAID E-042-2018-0-JP-06 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE JP National Stage 2019-565890 Issued
NIAID E-042-2018-0-PCT-02 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE PCT PCT PCT/US2018/034848 Expired
NIAID E-042-2018-0-CN-04 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE CN National Stage 201880048358.8 Pending
NIAID E-042-2018-0-EP-05 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE EP National Stage 18733056.8 Pending
NIAID E-067-2016-3-EP-02 METHOD OF VACCINATION WITH AN ATTENUATED RSV VACCINE
FORMULATION 		EP National Stage 16794904.9 Abandoned
NIAID E-042-2018-0-CA-03 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE CA National Stage 3064267 Pending
NCATS E-257-2010-0-IL-21 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators IL DIV 259648 Issued
NCATS E-004-2016-0-JP-07 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF JP National Stage 2018-527799 Issued
NCATS E-004-2016-0-US-08 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF US National Stage 15/779,353 10508106 Issued PDF
NIAID E-052-2017-4-NZ-39 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection NZ National Stage 742825 Abandoned
NIAID E-052-2017-4-KR-34 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection KR National Stage 10-2018-7014534 Abandoned
NCI E-213-2014-0-JP-05 Methodology For Astatination And Radioiodination Based On Iodonium Salt Precursors JP National Stage 2018-545695 Issued
NIAID E-191-2018-0-US-01 Improved Methods Of Manufacturing Peptide-Based Vaccines US 62/674,752 Abandoned
NIAID E-202-2008-0-US-18 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS US DIV 15/984,956 10881669 Issued PDF
NCI E-213-2014-0-US-06 Methodology For Astatination And Radioiodination Based On Iodonium Salt Precursors US National Stage 15/777,828 10703708 Issued PDF
NCI E-285-2016-2-EP-04 Glypican 2 As A Cancer Marker And Therapeutic Target EP National Stage 16864859.0 Issued
NCI E-285-2016-2-GB-01 Glypican 2 As A Cancer Marker And Therapeutic Target GB EP 16864859.0 Issued
NCI E-285-2016-2-LU-01 Glypican 2 As A Cancer Marker And Therapeutic Target LU EP 16864859.0 Issued
NCI E-285-2016-2-LT-01 Glypican 2 As A Cancer Marker And Therapeutic Target LT EP 16864859.0 Issued
NCI E-285-2016-2-LV-01 Glypican 2 As A Cancer Marker And Therapeutic Target LV EP 16864859.0 Issued
NCI E-285-2016-2-SI-01 Glypican 2 As A Cancer Marker And Therapeutic Target SI EP 16864859.0 Issued